Technical Description
This invention relates to novel 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline compounds designed for therapeutic use. These derivatives specifically target itch sensations associated with atopic diseases that are often resistant to standard medical treatments.
Problems Addressed
- Inadequate Antipruritics and Steroids
- Insufficient Antihistamine Efficacy
- Ineffective Postponed Relief
- Absence of Treatment Control
- Not Effective Current Drugs (Atopic)
Tech Features
- Enhanced Antipruritic Action
- Efficient Early-Stage Relief
- Efficient Topical Delivery
- Enhanced Metabolic Stability
- Enhanced Therapeutic Safety
Target Audience
- Dermatology Healthcare Sectors
- Topical Formulation Industries
- Specialty Chemical Industries
- Drug Distribution Sectors
- Research & Development
Tech ID: P27-1963 TRL 5 Patent Status: Granted Available For Exclusive and Non-exclusive License
